Use causes platelet count nadir of about 75,000.
Bleeding associated with abciximab best treated with discontinuation of the drug infusion and platelet transfusions.
Potent inhibitor of platelet glycoprotein IIb/IIIa receptor.
Greater frequency of both major (2.4%) and minor bleeding (14%) in patients treated with abciximab during percutaneous coronary interventions compared to percutaneous interventions alone.
Bleeding complications with abciximab and percutaneous coronary interventions are increased in the setting of an acute myocardial infarction.
Enhances the effectiveness of thrombolysis in the setting of acute coronary artery syndromes.
Initiated before catheterization improves outcomes in patients with acute myocardial infarction who are treated with primary stenting.
Early administration in patients with acute myocardial infarction improves coronary patency before stenting, the success rate of the stenting procedure, the rate of coronary patency at six months, left ventricular function, and clinical outcomes.
Use after pretreatment with clopidogrel does result in further clinical benefit in patients undergoing elective percutaneous coronary intervention.